Trial Profile
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 24 Feb 2021 Primary endpoint (Intraocular Pressure (IOP)) has been met, as per results published in the Advances in Therapy.
- 24 Feb 2021 Results published in the Advances in Therapy
- 14 Nov 2019 Status changed from active, no longer recruiting to completed.